Alkermes plc EBIT

The latest EBIT for ALKS is $160M as of June 2026. That compares with $390M in the prior-year period — down 59.5% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Alkermes plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, ALKS's EBIT moved from $390M to $160M — a 59.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Alkermes plc's operating scale or balance-sheet position.

Against Healthcare companies, ALKS currently prints $160M for EBIT, while the sector average sits near $23B. That is roughly 99.3% below the sector mean. Large gaps often invite a closer look at Alkermes plc's growth, margins, and balance sheet.

A EBIT figure of $160M for ALKS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting ALKS's EBIT ($160M), review year-over-year change from $390M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.